Ergoteles’s Cabaletta Bio CABA Stock Holding History

Ergoteles’s Portfolio CABA Stock Details CABA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-50,733	Closed	-$617K	–	1260
2021 Q3	$617K	Sell	50,733 -5,267	-9%	-$48.6K	0.02%	506
2021 Q2	$482K	Buy	+56,000	New	+$550K	0.01%	823

Other funds holding CABA

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ergoteles's CABA Position: Q4 2021 in Review

Ergoteles sold out of Cabaletta Bio (CABA) in Q4 2021, closing a stake of 50,733 shares — an estimated $617K sold.

Ergoteles first reported a position in CABA in Q2 2021 and held it in 2 quarters. The position peaked at $617K in Q3 2021. 66 funds tracked by Wall St. Rank hold CABA as of Q4 2021.

Ergoteles reported no remaining Cabaletta Bio position as of Q4 2021 after selling out during the quarter.
Ergoteles sold 50,733 Cabaletta Bio shares in Q4 2021, an estimated $617K.
Ergoteles first reported a position in Cabaletta Bio in Q2 2021 and held it in 2 quarters.
Ergoteles's Cabaletta Bio position peaked at $617K in Q3 2021.
66 funds tracked by Wall St. Rank held Cabaletta Bio as of Q4 2021.

Based on Ergoteles's 13F filing for Q4 2021, filed 14 Feb 2022.